Even high-dose extended infusions may not yield desired concentrations of β-lactams: The value of therapeutic drug monitoring

Infectious Diseases

Volumn 47, Issue 10, 2015, Pages 739-742

  Cotta, Menino Osbert ^a,b   Gowen, Belinda ^b   Truloff, Natasha ^b   Bursle, Evan ^b,c   McWhinney, Brett ^c   Ungerer, Jacobus P J ^c   Roberts, Jason A ^a,b   Lipman, Jeffrey ^a,b  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b ROYAL BRISBANE AND WOMEN'S HOSPITAL   (Australia)

^c Pathology Queensland ^*  (Australia)

Author keywords

Critically ill; Extended infusions; Therapeutic drug monitoring; Lactams

Indexed keywords

AMIKACIN; CIPROFLOXACIN; CREATININE; GENTAMICIN; MEROPENEM; PIPERACILLIN PLUS TAZOBACTAM; ANTIINFECTIVE AGENT; BETA LACTAM; THIENAMYCIN DERIVATIVE;

ADULT; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIBIOTIC THERAPY; ARTICLE; BLOOD CULTURE; BURN; CASE REPORT; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; CRITICALLY ILL PATIENT; DRUG BLOOD LEVEL; DRUG MEGADOSE; DRUG MONITORING; EDEMA; ENTEROCOCCUS FAECALIS; ESCHERICHIA COLI; FEMALE; FEVER; HUMAN; INFLAMMATION; INJURY SEVERITY; INTENSIVE CARE; KIDNEY FUNCTION; KLEBSIELLA OXYTOCA; MINIMUM INHIBITORY CONCENTRATION; PRESCRIPTION; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTION; SEPSIS; TREATMENT RESPONSE; CRITICAL ILLNESS; DOSE RESPONSE; DRUG EFFECTS; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; PSEUDOMONAS INFECTIONS;

ADULT; AMIKACIN; ANTI-BACTERIAL AGENTS; BETA-LACTAMS; CRITICAL ILLNESS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG MONITORING; DRUG RESISTANCE, BACTERIAL; FEMALE; HUMANS; MICROBIAL SENSITIVITY TESTS; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; SEPSIS; THIENAMYCINS;

EID: 84962547518     PISSN: 23744235     EISSN: None     Source Type: Journal    
DOI: 10.3109/23744235.2015.1021831     Document Type: Article

References (20)

1. Jamal JA, Economou C, Lipman J, Roberts JA Improving antibiotic dosing in special situations in the ICU: burns, renal replacement therapy and extracorporeal membrane oxygenation Curr Opin Crit Care 2012; 18: 460-71.
2. Fitzwater J, Purdue G, Hunt J, O' K eefe G.The risk factors and time course of sepsis and organ dysfunction after burn trauma JTrauma 2003; 54: 959-66.
3. Queensland Health State of our Public Hospitals in Queensland Brisbane; 2007.
4. Chim H, Tan B, Song C.Five-year review of infections in a burn intensive care unit: high incidence of Acinetobacter baumannii in a tropical climate Burns 2007; 33: 1008-14.
5. Sinnollareddy M, Roberts M, Lipman J, Roberts J.?-lactam pharmacokinetics and pharmacodynamics in critically ill patients and strategies for dose optimization: a structured review Clin Exp Pharmacol Physiol 2012; 39: 489-96.
6. Mouton J, Vinks AA Continuous infusion of beta-lactams Curr Opin Crit Care 2007; 13: 598-606.
7. Patel B, Paratz J, See N, Muller M, Rudd M, Paterson D, et al Therapeutic drug monitoring of beta-lactam antibiotics in burns patients-A one-year prospective study Ther Drug Monit 2012; 34: 160-4.
8. Turnidge J.The pharmacodynamics of beta-lactams Clin Infect Dis 1998; 27: 10-22.
9. Manduru M, Mihm L, White R, Friedrich L, Flume P, Bosso J.In vitro pharmacodynamics of ceftazidime against Pseudomonas aeruginosa isolates from cystic fibrosis patients Antimicrob Agents Chemother 1997; 41: 2053-6.
10. Tam V, McKinnon P, Akins R, Rybak M, Drusano G.Pharmacodynamics of cefepime in patients with Gram-negative infections JAntimicrob Chemother 2002; 50: 425-8.
11. Tam V H, Schilling A, Neshat S, Poole K, Melnick D, Coyle E.Optimization of meropenem minimum concentration/MIC ratio to suppress in vitro resistance of Pseudomonas aeruginosa Antimicrob Agents Chemother 2005; 49: 4920-7.
12. Li C, Du X, Kuti J, Nicolau D.Clinical pharmacodynamics of meropenem in patients with lower respiratory tract infections Antimicrob Agents Chemother 2007; 51: 1725-30.
13. Craig W.Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men Clin Infect Dis 1998; 26: 1-12
14. G erber A, Vastola A, Brandel J, Craig WA Selection of aminoglycoside-resistant variants of Pseudomonas aeruginosa in an in vivo model JInfect Dis 1982; 146: 691-7.
15. Nasser S, Mabrouk A, Maher A.Colonization of burn wounds in Ain Shams University Burn Unit Burns 2003; 29: 229-33.
16. Pirnay J-P, De Vos D, Cochez C, Bilocq F, Pirson J, Struelens M, et al Molecular epidemiology of Pseudomonas aeruginosa colonization in a burn unit: persistence of a multidrug-resistant clone and a silver sulfadiazine-resistant clone J Clin Microbiol 2003; 41: 1192-202.
17. Roberts JA, Lipman J.Pharmacokinetic issues for antibiotics in the critically ill patient Crit Care Med 2009; 37: 840-51.
18. Udy A A, Roberts JA, Shorr A F, Boots RJ, Lipman J.Augmented renal clearance in septic and traumatized patients with normal plasma creatinine concentrations: identifying at-risk patients Crit Care 2013; 17: R35.
19. Lorente L, Lorenzo L, Martín M, Jimnez A, Mora M.Meropenem by continuous versus intermittent infusion in ventilator-Associated pneumonia due to gram-negative bacilli Ann Pharmacother 2006; 40: 219-23.
20. Wong G, Brinkman A, Benefield R J, Carlier M, De Waele J J, El Helali N, et al An international, multicentre survey of ?-lactam antibiotic therapeutic drug monitoring practice in intensive care units JAntimicrob Chemother 2014; 69: 1416-23.